• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by BioHarvest Sciences Inc.

    5/15/25 4:26:58 PM ET
    $BHST
    Get the next $BHST alert in real time by email
    6-K 1 bhsc_6k.htm REPORT Report

     

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of May 2025

     

    Commission file number: 001-42389

     

    BIOHARVEST SCIENCES INC.

    (Exact name of Registrant as specified in its charter)

     

    Not applicable

    (Translation of Registrant’s name into English)

     

    1140-625 Howe Street, Vancouver, British Columbia V6C 2T6, Canada

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    ☐ Form 20-F ☒ Form 40-F

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

     

     

     

     

     

     

     

     

     

     

     

     

     

     


     

    SUBMITTED HEREWITH

     

    Exhibits:

     

    Exhibit

    Description

    99.1

    Unaudited Interim Condensed Consolidated Financial Statements For the Three Months Ended March 31, 2025

    99.2

    Management’s Discussion and Analysis For the three months ended March 31, 2025

    99.3

    Form 52-109F2 - Certification of Interim Filings – Full Certificate - CEO

    99.4

    Form 52-109F2 - Certification of Interim Filings – Full Certificate - CFO

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     


     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

    BIOHARVEST SCIENCES INC.

     

    (Registrant)

     

     

    Date: May 15, 2025

    /s/ David Ryan

     

    Name: David Ryan

     

    Title: Vice-President, Investor Relations & Secretary

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $BHST alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BHST

    DatePrice TargetRatingAnalyst
    5/5/2025$15.00Buy
    Craig Hallum
    12/18/2024$12.00Buy
    Maxim Group
    More analyst ratings

    $BHST
    Financials

    Live finance-specific insights

    See more
    • BioHarvest Sciences Reports First Quarter 2025 Financial Results

      First Quarter Revenues Grew 47% to $7.9 Million, Exceeding Management GuidanceRehovot, Israel--(Newsfile Corp. - May 15, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the first quarter ended March 31, 2025.First Quarter & Subsequent 2025 Operational HighlightsAll figures stated in this news release are in U.S. dollars unless stated otherwise. Total revenues for the first quarter of 2025 increased 47% year-over-year to $7.9 million, exceeding management guidance, with gross margins expanding by 227 basis points to 58.

      5/15/25 4:05:00 PM ET
      $BHST
    • BioHarvest Sciences to Host First Quarter 2025 Earnings Call on May 15 at 4:30 p.m. Eastern Time

      Rehovot, Israel--(Newsfile Corp. - May 1, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 15, 2025.Management will host an investor conference call and webcast at 4:30 p.m. Eastern time on Thursday, May 15, 2025 to discuss the Company's first quarter 2025 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate, please use the following information:First Quarter

      5/1/25 8:30:00 AM ET
      $BHST
    • BioHarvest Sciences Reports Fourth Quarter and Full Year 2024 Financial Results

      Fourth Quarter Revenues Grew 62% to $7.3 Million, Exceeding Prior Management Guidance, with Full Year Revenues Increasing 99% Year-Over-Year to $25.2 MillionCDMO Division Secures Anchor Partnership with Tate & Lyle to Develop Next Generation of Plant-Based SweetenersRehovot, Israel--(Newsfile Corp. - March 31, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2024.Fourth Quarter 2024 & Subsequent Operational HighlightsAll figures stated in this news release are in U.S.

      3/31/25 4:05:00 PM ET
      $BHST

    $BHST
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioHarvest Sciences Reports First Quarter 2025 Financial Results

      First Quarter Revenues Grew 47% to $7.9 Million, Exceeding Management GuidanceRehovot, Israel--(Newsfile Corp. - May 15, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the first quarter ended March 31, 2025.First Quarter & Subsequent 2025 Operational HighlightsAll figures stated in this news release are in U.S. dollars unless stated otherwise. Total revenues for the first quarter of 2025 increased 47% year-over-year to $7.9 million, exceeding management guidance, with gross margins expanding by 227 basis points to 58.

      5/15/25 4:05:00 PM ET
      $BHST
    • BioHarvest Announces Completion of Stage 1 Development for CDMO Contract with Nasdaq-Listed Pharmaceutical Company

      Successful Progression Validates Botanical Synthesis Platform for a Variety of Molecule TypesRehovot, Israel--(Newsfile Corp. - May 12, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company's previously announced CDMO contract with a Nasdaq-listed pharmaceutical company has progressed from Stage 1 to Stage 2 - providing further validation of the versatility of the Company's Botanical Synthesis platform to develop active pharmaceutical compounds while concurrently paving the road for potential future volume manufacturing. Stage 1 of the contract, la

      5/12/25 8:30:00 AM ET
      $BHST
    • BioHarvest Sciences to Host First Quarter 2025 Earnings Call on May 15 at 4:30 p.m. Eastern Time

      Rehovot, Israel--(Newsfile Corp. - May 1, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 15, 2025.Management will host an investor conference call and webcast at 4:30 p.m. Eastern time on Thursday, May 15, 2025 to discuss the Company's first quarter 2025 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate, please use the following information:First Quarter

      5/1/25 8:30:00 AM ET
      $BHST

    $BHST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on BioHarvest Sciences with a new price target

      Craig Hallum initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $15.00

      5/5/25 8:30:45 AM ET
      $BHST
    • Maxim Group initiated coverage on BioHarvest Sciences with a new price target

      Maxim Group initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $12.00

      12/18/24 8:10:03 AM ET
      $BHST

    $BHST
    SEC Filings

    See more
    • SEC Form 6-K filed by BioHarvest Sciences Inc.

      6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

      5/15/25 4:49:56 PM ET
      $BHST
    • SEC Form 6-K filed by BioHarvest Sciences Inc.

      6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

      5/15/25 4:26:58 PM ET
      $BHST
    • SEC Form 6-K filed by BioHarvest Sciences Inc.

      6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

      5/12/25 4:23:22 PM ET
      $BHST

    $BHST
    Leadership Updates

    Live Leadership Updates

    See more
    • BioHarvest Announces Appointment of Sharon Malka to Board of Directors

      Veteran Technology Leader Brings 25+ Years of Financial and Capital Markets Experience to the BoardVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 22, 2025) - BioHarvest Sciences Inc., (NASDAQ:BHST) (CSE:BHSC) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today announced that Mr. Sharon Malka has agreed to serve as an independent director of BioHarvest. The appointment is effective immediately."We are very pleased to announce the addition of Mr. Malka to the BioHarvest Board of Directors," said Dr. Zaki Rakib, Chairman of the Board and President of BioHarvest Sciences' CDMO Services Division

      1/22/25 8:30:00 AM ET
      $BHST